202 related articles for article (PubMed ID: 35883203)
1. Generation of an mESC model with a human hemophilia B nonsense mutation via CRISPR/Cas9 technology.
Ma Y; Sun W; Zhao L; Yao M; Wu C; Su P; Yang L; Wang G
Stem Cell Res Ther; 2022 Jul; 13(1):353. PubMed ID: 35883203
[TBL] [Abstract][Full Text] [Related]
2. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
[TBL] [Abstract][Full Text] [Related]
3. Paired CRISPR/Cas9 Nickases Mediate Efficient Site-Specific Integration of
Wang Y; Zhao J; Duan N; Liu W; Zhang Y; Zhou M; Hu Z; Feng M; Liu X; Wu L; Li Z; Liang D
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301136
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice.
Huai C; Jia C; Sun R; Xu P; Min T; Wang Q; Zheng C; Chen H; Lu D
Hum Genet; 2017 Jul; 136(7):875-883. PubMed ID: 28508290
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse.
Guan Y; Ma Y; Li Q; Sun Z; Ma L; Wu L; Wang L; Zeng L; Shao Y; Chen Y; Ma N; Lu W; Hu K; Han H; Yu Y; Huang Y; Liu M; Li D
EMBO Mol Med; 2016 May; 8(5):477-88. PubMed ID: 26964564
[TBL] [Abstract][Full Text] [Related]
6. The Molecular Basis of FIX Deficiency in Hemophilia B.
Shen G; Gao M; Cao Q; Li W
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269902
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs.
Morishige S; Mizuno S; Ozawa H; Nakamura T; Mazahery A; Nomura K; Seki R; Mouri F; Osaki K; Yamamura K; Okamura T; Nagafuji K
Int J Hematol; 2020 Feb; 111(2):225-233. PubMed ID: 31664646
[TBL] [Abstract][Full Text] [Related]
8. Advanced cell-based modeling of the royal disease: characterization of the mutated F9 mRNA.
Martorell L; Luce E; Vazquez JL; Richaud-Patin Y; Jimenez-Delgado S; Corrales I; Borras N; Casacuberta-Serra S; Weber A; Parra R; Altisent C; Follenzi A; Dubart-Kupperschmitt A; Raya A; Vidal F; Barquinero J
J Thromb Haemost; 2017 Nov; 15(11):2188-2197. PubMed ID: 28834196
[TBL] [Abstract][Full Text] [Related]
9. PAM-flexible Cas9-mediated base editing of a hemophilia B mutation in induced pluripotent stem cells.
Hiramoto T; Kashiwakura Y; Hayakawa M; Baatartsogt N; Kamoshita N; Abe T; Inaba H; Nishimasu H; Uosaki H; Hanazono Y; Nureki O; Ohmori T
Commun Med (Lond); 2023 Apr; 3(1):56. PubMed ID: 37076593
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Mediated In Situ Introduction or Integration of
Tang Q; Hu Z; Zhao J; Zhou T; Tang S; Wang P; Xiao R; Chen Y; Wu L; Zhou M; Liang D
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240366
[TBL] [Abstract][Full Text] [Related]
11. Genetic Correction and Hepatic Differentiation of Hemophilia B-specific Human Induced Pluripotent Stem Cells.
He Q; Wang HH; Cheng T; Yuan WP; Ma YP; Jiang YP; Ren ZH
Chin Med Sci J; 2017 Sep; 32(3):135-144. PubMed ID: 28956740
[TBL] [Abstract][Full Text] [Related]
12. Generation an induced pluripotent stem cell line SXMUi001-A derived from a hemophilia B patient carries variant F9 c.223C＞T(p.R75X).
Ma Y; Sun W; Liu X; Ren J; Zhang X; Zhang R; Zhao L; Yang L; Wang G
Stem Cell Res; 2022 Apr; 60():102684. PubMed ID: 35121195
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9-mediated knockin of human factor IX into swine factor IX locus effectively alleviates bleeding in hemophilia B pigs.
Chen J; An B; Yu B; Peng X; Yuan H; Yang Q; Chen X; Yu T; Wang L; Zhang X; Wang H; Zou X; Pang D; Ouyang H; Tang X
Haematologica; 2021 Mar; 106(3):829-837. PubMed ID: 31974191
[TBL] [Abstract][Full Text] [Related]
14. Hemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche T; Chuah MK
Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
[TBL] [Abstract][Full Text] [Related]
15. Gene Therapy Approaches for the Treatment of Hemophilia B.
Soroka AB; Feoktistova SG; Mityaeva ON; Volchkov PY
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445943
[TBL] [Abstract][Full Text] [Related]
16. MiR-128 and miR-125 regulate expression of coagulation Factor IX gene with nonsense mutation by repressing nonsense-mediated mRNA decay.
Wang G; Chai B; Yang L
Biomed Pharmacother; 2016 May; 80():331-337. PubMed ID: 27133073
[TBL] [Abstract][Full Text] [Related]
17. [Advances in AAV-CRISPR/Cas9-Mediated Hemophilia A Gene Therapy --Review].
Fang S; Wang G; Yang LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1890-1893. PubMed ID: 38071078
[TBL] [Abstract][Full Text] [Related]
18. Apparent synonymous mutation F9 c.87A>G causes secretion failure by in-frame mutation with aberrant splicing.
Odaira K; Tamura S; Suzuki N; Kakihara M; Hattori Y; Tokoro M; Suzuki S; Takagi A; Katsumi A; Hayakawa F; Okamoto S; Suzuki A; Kanematsu T; Matsushita T; Kojima T
Thromb Res; 2019 Jul; 179():95-103. PubMed ID: 31102861
[TBL] [Abstract][Full Text] [Related]
19. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
[TBL] [Abstract][Full Text] [Related]
20. [A quick and efficient method to generate hemophilia B mouse models by the CRISPR/Cas system].
Wang QH; Huai C; Sun R; Zhuang H; Chen HY; Fei J; Lu DR
Yi Chuan; 2015 Nov; 37(11):1143-8. PubMed ID: 26582528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
